A Phase 2/3 interventional study of Dexmedetomidine and Placebo in Traumatic Brain Injury and Agitation,Psychomotor, sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dexmedetomidine in Brain Injuries, Traumatic — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Brain Injuries, Traumatic.
Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 2/3, and was the 5th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →5 of the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18–65
Aswan University · Sites in Egypt
Ages 18+
Benha University
Ages 18+
Assiut University
Ages 18–45
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 3
First in 2010; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 76 across the 10 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal is the lead sponsor of 34 studies on the registry; 16 are open to participants now.
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal has 1 study filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
1 of the studies testing dexmedetomidine in Brain Injuries, Traumatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07807579Assiut UniversityImpact of Dexmedetomidine Versus Propofol on Intracranial Pressure in Adult Traumatic Brain Injury Patients: Randomized Controlled Double-Blind Trial | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing dexmedetomidine in Brain Injuries, Traumatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Agitation is a frequent complication following traumatic braing injury in patients admitted to the intensive care unit. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine may be a better agent given it's light sedative properties. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU.
Following a traumatic brain injury, agitation is reported in 53-57% of patients in the intensive care unit. As it is associated with accidental removal of catheters, tubes and dressings as well as self-extubation, agitation poses a threat to patient safety. In addition, agitation can be accompanied by aggressive behaviors that pose a threat to clinician safety. This agitation frequently results in the liberal use of rescue drugs such as antipsychotics, sedatives and opiates, which in turn may delay rehabilitation, liberation from mechanical ventilation and emergence from posttraumatic amnesia. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist used for sedation and also has co-analgesic and withdrawal syndrome alleviating properties. Unlike other sedatives, patients remain easily roused when under dexmedetomidine, facilitating contact and removal from mechanical ventilation. In addition, dexmedetomidine does not induce respiratory depression in critically ill patients. The addition of dexmedetomidine may have the potential to reduce the incidence agitation while reducing the use of agitation rescue drugs such as antipsychotics, the use of physical restraints, as well as the time to cessation of mechanical ventilation and consequently, reduce the time to emergence for post-traumatic amnesia. Duration of posttraumatic amnesia is an important outcome as it is a predictor of cognitive and functional outcomes as well as community integration, psychosocial functioning and employment. The main objective is to assess the feasibility of conducting a multicenter randomized controlled trial of dexmedetomidine following TBI in the ICU. To evaluate the feasibility of conducting a large trial and to refine study procedures, a multicenter randomized double-blind placebo-controlled pilot study comparing dexmedetomidine to placebo will be conducted. The feasibility outcomes will include protocol adherence, trial recruitment and time-in-motion evaluation for study procedures. Clinical outcomes will include agitation, exposure to antipsychotics, time to emergence from post-traumatic amnesia, physical restraint use, ventilator days, and time to ICU and hospital discharge as well as ICU and hospital mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
DEX (4 mcg/100 ml supplied by Juno Pharmaceuticals) will be initiated at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
Drug: Dexmedetomidine
Matching placebo (NS 0.9% 100ml)
Drug: Placebo
DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
Also known as: Precedex
NaCl 0.9% 100ml
Protocol adherence
Proportion of hours the drug was administered
Time frame: Through study completion, an average of 2 years
Trial recruitment
Recruitment rate and randomization/activation process (consent rate, proportion of recruited patients who receive the study drug)
Time frame: Through study completion, an average of 2 years
Blinding maintenance
Proportion of intensivists and nurses predicting study group assignment at the end of the study intervention and proportion of patients receiving propofol
Time frame: Through study completion, an average of 2 years
Proportion of data collection completed
Data collection completeness for agitation-related events, posttraumatic amnesia and cognitive recovery
Time frame: Through study completion, an average of 2 years
ICU-days free of agitation or coma within 14 days following randomization
Number of ICU-days without agitation or coma within 14 days following randomization
Time frame: During ICU stay up to 14 days
Agitation-related event during the ICU stay
Accidental device removal, self-extubation following randomization in the ICU
Time frame: Through study completion, an average of 2 years
Proportion of patients and the number of days exposed to antipsychotics, benzodiazepines and physical restraints
Exposure to antipsychotics, benzodiazepines and physical restraints after randomization during ICU stay
Time frame: Through study completion, an average of 2 years
Time to mechanical ventilation liberation (extubation), time to ICU and hospital discharge
Time to mechanical ventilation liberation (extubation), time to ICU and hospital discharge
Time frame: Through study completion, an average of 2 years
Time to emergence from posttraumatic amnesia
Time from randomisation to emergence from posttraumatic amnesia
Time frame: Through study completion, an average of 2 years
Cognitive recovery
Brief cognitive assessment in traumatology (EXACT) score (0-100 points); higher scores reflect better function
Time frame: Through study completion, an average of 2 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2024; primary completion for Jun 2026, 20 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal